







JOB OFFER							
REFERENCE	REFERENCE		IG DATE	DEADLINE			
2021.051	2021.051			06/11/2022			
PROFILE REQUIREMENTS							
EXCLUSIVE REQUIREMENTS: (1)							
ACADEMIC DEGREE							
VALUED MERITS /SKYLLS							
FORMATION	Office automation advanced user level						
EXPERIENCE	<ul> <li>Knowledge in hematology, especially hematopoietic progenitor transplantation.</li> <li>Database maintenance</li> <li>Experience and knowledge in clinical trials</li> <li>Experience in biomedical research</li> </ul>						
LANGUAGES English level (minimum B2)							
CONTRACT INFORMATION							
TYPE OF CONTRACT		EXPECTED INCORPORATION DATE		JOB STATUS			
*Indefinite linked to line of investigation			2/2022 Full (35h/week)				
ANNUAL GROSS SALARY			DURATION OF THE CONTRACT				
20.713,61 €			It will depend on the duration of the project and the economic availability based on RDL8/2022.				
WORK LOCATIONS		NS	UN	UNIT/DEPARTMENT			
Pavilion 20, consultation rooms and Hematology floor. Clinical Trials Clinical Trials			Hematology/Clinical Trials				
OFFER DESCRIPTION							
		Research supp	oort technician				
	DESCRI	PTION OF THE	TASKS IN THE I	PROJECT			
<ul> <li>Collection and entry of data in the different platforms of the hematology service: EBMT (ProMISe: Med-B), Valtermed and others that may be determined.</li> <li>Collection and entry of clinical trial data into data collection notebooks.</li> <li>Resolving discrepancies (queries).</li> <li>Performing database cutoffs within established deadlines.</li> <li>Support as Data Manager to the hematology service staff in the development of the Clinical Trial.</li> </ul>							









Participation in the training of new personnel.							
PRINCIPA INVESTIGAT RESPONSA	OR / RESEARCH GROUP RESEARCH		сн ргојест				
Enrique María Oo Miguel	cio San	Hematological Neoplasms an Hematopoietic Progenitor Transplantation Hematopoietic Progenitor Transplantation	<ul> <li>multicéntrico para o pauta recomendada y la eficacia prelin combinación con tr sujetos con mielom refractario (MMRR)</li> </ul>	9.227: Estudio de fase I/II, abierto y lticéntrico para determinar la dosis y la ta recomendadas y evaluar la seguridad a eficacia preliminar del CC-92480 en nbinación con tratamientos estándar en etos con mieloma múltiple en recaída o actario (MMRR) y mieloma múltiple de vo diagnóstico (MMND)			
RECRUITMENT INFORMATION							
SELECTION PRO	EMPLOYMENT EXCHANGE						
Pre-selection Interview: maxi Minimum score f Report of the Se Resolution	: 5 SI						
SELECTION BOARD							
<ul> <li>Enrique Ocio San Miguel, Principal Investigator of the Research Project</li> <li>Galo Peralta, Management Director of IDIVAL</li> <li>Patricia Álvarez Ingelmo, HR Coordinator (will act as Secretary of the Tribunal)</li> <li>VALUATION OF MERITS</li> </ul>							
MERITS	EVALUA	TION	MAXIMUM				
Knowledge in hematology, especially hematopoietic progenitor transplantation	Curricula	r Months wor	ked 1 point per month worke	d 20			
Office automation advanced user	Curricula	r Merit fulfillment	1 point per month worke	d 10			
Database maintenance	Curricula	r Merit fulfillment	YES/NO	10			
Biomedical research experience	Curricula	r Merit fulfillment	YES/NO	10			
Experience and							
expertise in clinical trials	Curricula	r fulfillment	YES/NO	5			
expertise in	Curricula Curricula	r fulfillment	YES/NO B2: 3 C1 o sup.: 5	5			
expertise in clinical trials		r fulfillment	B2: 3 C1 o sup.: 5				
expertise in clinical trials	Curricula	r fulfillment r Level FINAL SCO	B2: 3 C1 o sup.: 5				









## MAXIMUM TOTAL SCORE

100

(1) Not subsanable(2) See duration of each phase in the document "Selection Process"

In compliance with the provisions of Article 11 of Organic Law 3/2018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at www.idival.org/es/Política-de-Privacidad